Please login to the form below
Dupixent
This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12
At 16 weeks, 68% of children on the higher dose, and 58% on the lower dose of Dupixent ‘achieved the primary endpoint of significant histological disease remission’. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of
Latest news
-
Sanofi and Regeneron receives FDA priority review for prurigo nodularis
Dupixent would be the first drug specifically indicated for the condition in the US. ... In both PRIME and PRIME2, the primary and key secondary endpoints were met and showed Dupixent significantly improved disease signs and symptoms versus placebo.
-
Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment
Dupixent is the first and only drug specifically recommended for EoE in the US. ... Following the FDA’s decision, Dupixent has become the first and only available medicine specifically recommended for the treatment of EoE in the US.
-
Sanofi’s asthma treatment approved by European Commission
Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation. ... Dupixent significantly reduces asthma attacks, helps children breathe better and improves their health-related quality of life.”.
-
Sanofi and Regeneron share positive trial results for patients with uncontrolled prurigo nodularis
It was shown that Dupixent significantly reduced itch and skin lesions compared to placebo in both trials. ... times as many Dupixent patients experienced a clinically meaningful reduction in itch from baseline at week 24.
-
Sanofi and Regeneron announce positive phase 3 trial results for Dupixent
Sanofi and Regeneron Pharmaceuticals have announced positive results from a second phase 3 trial, showing Dupixent (dupilumab) – when administered in 300mg doses weekly – significantly improved the signs and symptoms of eosinophilic ... Additionally,
More from news
Approximately 28 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
Videum Health
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
